Pharmacological treatments of COVID-19

Sahebnasagh, A. and Avan, R. and Saghafi, F. and Mojtahedzadeh, M. and Sadremomtaz, A. and Arasteh, O. and Tanzifi, A. and Faramarzi, F. and Negarandeh, R. and Safdari, M. and Khataminia, M. and Rezai Ghaleno, H. and Habtemariam, S. and Khoshi, A. (2020) Pharmacological treatments of COVID-19. Pharmacological Reports, 72 (6). pp. 1446-1478.

Preview

Text Pharmacological-treatments-of-COVID192020Pharmacological-Reports.pdf Download (1MB) | Preview

Abstract

The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19), which was reported for the first time in December 2019, was named by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2), because of the very similar genome and also its related symptoms to SARS-CoV1. The ongoing COVID-19 pandemic with significant mortality, morbidity, and socioeconomic impact is considered by the WHO as a global public health emergency. Since there is no specific treatment available for SARS-CoV2 infection, and or COVID-19, several clinical and sub-clinical studies are currently undertaken to find a gold-standard therapeutic regimen with high efficacy and low side effect. Based on the published scientific evidence published to date, we summarized herein the effects of different potential therapies and up-to-date clinical trials. The review is intended to help readers aware of potentially effective COVID-19 treatment and provide useful references for future studies. © 2020, Maj Institute of Pharmacology Polish Academy of Sciences.

Actions (login required)

View Item